Evidence map›Paper›PMID 35197550›Full record

ArticleCommunications biology2022

Fortilin interacts with TGF-β1 and prevents TGF-β receptor activation.

Decha Pinkaew, Erik Martinez-Hackert, Wei Jia, Matthew D King, Fei Miao, Nicole R Enger, Runglawan Silakit, Kota Ramana, Shi-You Chen, Ken Fujise

Open access · goldAbstract read
In one paragraph

Article in Communications biology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.1field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Protein-Protein Binding Kinetics by Biolayer Interferometry.Advances in experimental medicine and biology · 2024
    Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 4 institutions in 1 country.

Decha PinkaewDivision of Cardiology, Department of Medicine, University of Washington, Seattle, WA, 98109, USA.ORCID http://orcid.org/0000-0001-8334-1545
Erik Martinez-HackertDepartment of Biochemistry and Molecular Biology, Michigan State University, East Lansing, MI, 48824, USA.ORCID http://orcid.org/0000-0002-6182-7023
Wei JiaDepartment of Surgery, University of Missouri, Columbia, MO, 65212, USA.
Matthew D KingDepartment of Chemistry and Biochemistry, Boise State University, Boise, ID, 83725, USA.
Fei MiaoDivision of Cardiology, Department of Medicine, University of Washington, Seattle, WA, 98109, USA.
Nicole R EngerDivision of Cardiology, Department of Medicine, University of Washington, Seattle, WA, 98109, USA.
Runglawan SilakitDivision of Cardiology, Department of Medicine, University of Washington, Seattle, WA, 98109, USA.
Kota RamanaDepartment of Biochemistry, Noorda College of Osteopathic Medicine, Provo, UT, 84606, USA.
Shi-You ChenDepartment of Surgery, University of Missouri, Columbia, MO, 65212, USA.
Ken FujiseDivision of Cardiology, Department of Medicine, University of Washington, Seattle, WA, 98109, USA. kfujise@uw.edu.ORCID http://orcid.org/0000-0002-6763-8055
University of Washington · USUniversity of Missouri · USBoise State University · USMichigan State University · US

Funding

Fortilin, p53, and atherosclerosisR01HL117247 · NHLBI · UNIVERSITY OF WASHINGTON · PI CHEN, SHIYOU, FUJISE, KEN · 2013 to 2023
$4.7M
Fortilin, CTNNA3, and the HeartR01HL152723 · NHLBI · UNIVERSITY OF WASHINGTON · PI FUJISE, KEN · 2021 to 2024
$2.7M
USING FORTILIN INHIBITORS TO BLOCK ATHEROSCLEROSISR01HL138992 · NHLBI · UNIVERSITY OF WASHINGTON · PI FUJISE, KEN, SRIVASTAVA, SANJAY · 2017 to 2020
$2.6M
Gut Dysbiosis and Cardiac Remodeling in IBDR01HL152683 · NHLBI · UNIVERSITY OF TEXAS MED BR GALVESTON · PI FUJISE, KEN, LI, QINGJIE · 2020 to 2023
$2.6M
TGF-β signaling and regulation: Elucidating molecular mechanisms and pathogenic functions of the ‘co-receptor’ Cripto-1 and the receptor BMPRIIR01GM121499 · NIGMS · MICHIGAN STATE UNIVERSITY · PI MARTINEZ HACKERT, ERIK MATTHIAS · 2018 to 2022
$1.5M
Characterization of Fortilin, A Novel Anti-p53 ProteinR01HL068024 · NHLBI · UNIVERSITY OF TEXAS HLTH SCI CTR HOUSTON · PI FUJISE, KEN · 2001 to 2005
$992k
NHLBI NIH HHS R01 HL068024NHLBI NIH HHS R01 HL117247NHLBI NIH HHS R01 HL138992NHLBI NIH HHS R01 HL152683NHLBI NIH HHS R01 HL152723NIGMS NIH HHS R01 GM121499U.S. Department of Health & Human Services | National Institutes of Health (NIH) HL117247U.S. Department of Health & Human Services | National Institutes of Health (NIH) HL138992U.S. Department of Health & Human Services | National Institutes of Health (NIH) HL152683U.S. Department of Health & Human Services | National Institutes of Health (NIH) HL152723
6 · The paper itself

Abstract

Fortilin is a 172-amino acid multifunctional protein present in both intra- and extracellular spaces. Although fortilin binds and regulates various cellular proteins, the biological role of extracellular fortilin remains unknown. Here we report that fortilin specifically interacts with TGF-β1 and prevents it from activating the TGF-β1 signaling pathway. In a standard immunoprecipitation-western blot assay, fortilin co-immunoprecipitates TGF-β1 and its isoforms. The modified ELISA assay shows that TGF-β1 remains complexed with fortilin in human serum. Both bio-layer interferometry and surface plasmon resonance (SPR) reveal that fortilin directly bind TGF-β1. The SPR analysis also reveals that fortilin and the TGF-β receptor II (TGFβRII) compete for TGF-β1. Both luciferase and secreted alkaline phosphatase reporter assays show that fortilin prevents TGF-β1 from activating Smad3 binding to Smad-binding element. Fortilin inhibits the phosphorylation of Smad3 in both quantitative western blot assays and ELISA. Finally, fortilin inhibits TGFβ-1-induced differentiation of C3H10T1/2 mesenchymal progenitor cells to smooth muscle cells. A computer-assisted virtual docking reveals that fortilin occupies the pocket of TGF-β1 that is normally occupied by TGFβRII and that TGF-β1 can bind either fortilin or TGFβRII at any given time. These data support the role of extracellular fortilin as a negative regulator of the TGF-β1 signaling pathway.

Indexed as

Receptors, Transforming Growth Factor betaTransforming Growth Factor beta1Tumor Protein, Translationally-Controlled 1HumansPhosphorylationSignal TransductionReceptors, Transforming Growth Factor betaTGFB1 protein, humanTPT1 protein, humanTransforming Growth Factor beta1Tumor Protein, Translationally-Controlled 1

Identifiers

PMID35197550
PMCPMC8866402
OpenAlexW4213007344

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.